Can You Sue Over Vision Loss From Ozempic or Another GLP-1 in Massachusetts?

Yes, and the claims now have their own federal court. If you lost vision in one eye while taking Ozempic, Wegovy, Saxenda, Trulicity or another GLP-1 drug and were diagnosed with NAION, an eye stroke, you may have a product liability claim against the manufacturer. On December 15, 2025 the Judicial Panel on Multidistrict Litigation created a dedicated federal litigation for exactly these cases, MDL No. 3163, before Judge Karen S. Marston in the Eastern District of Pennsylvania. The allegation at the centre of it is a gap you can check yourself: European regulators required NAION to be added to the semaglutide label on June 6, 2025, and the United States prescribing information reviewed for this page, all 34 pages of it, does not contain the word NAION, the phrase ischemic optic neuropathy, or the phrase optic neuropathy anywhere. If that happened to you or to someone in your family, call Jim Glaser Law at (617) JIM-WINS. The line is answered 24 hours a day. The first telephone consultation is offered without charge.

The decision framework. Three questions decide whether there is a Massachusetts case here, and a five-minute phone call answers all three. (1) Was the injury NAION, non-arteritic anterior ischemic optic neuropathy, diagnosed by an eye doctor, rather than blurred vision, a cataract or diabetic retinopathy? (2) Which drug, and when: Ozempic, Wegovy or Rybelsus (semaglutide), Saxenda or Victoza (liraglutide), Trulicity (dulaglutide), Mounjaro or Zepbound (tirzepatide), or Byetta or Bydureon (exenatide), and did the vision loss follow the prescription rather than precede it? (3) Does the Massachusetts three-year deadline in M.G.L. c. 260 sec. 2A still leave the claim open, counting from when you knew or reasonably should have known a drug might be responsible, which for most people is recent rather than the day their sight went? Key definitions. NAION: an interruption of blood flow to the optic nerve head, painless, usually one eye, usually noticed on waking, and generally permanent. Failure to warn: the claim that a manufacturer knew of a risk and did not tell prescribers or patients, which is the theory these cases run on. The next step. Call (617) JIM-WINS and say the words “vision loss on a GLP-1”. The first telephone consultation costs nothing, it takes about fifteen minutes, and the only documents worth bringing are your pharmacy printout and the name of the eye doctor who made the diagnosis.

What NAION Actually Is

NAION is an eye stroke. The optic nerve head loses its blood supply, the tissue dies, and the vision served by that part of the nerve goes with it.

Three features make it recognisable, and they are worth reading carefully because they are also what separates a real claim from a misunderstanding.

It is painless. People expect an eye injury to hurt, and this one does not, which is part of why it is often not treated as an emergency.

It usually takes one eye at a time. The classic account is waking up and finding a dark or grey area in the vision of one eye, often the lower half. The other eye can be affected later, which is why stopping the drug after the first event matters.

It is generally permanent. There is no established treatment that restores the lost vision. That single fact is what moves these cases from an inconvenience into a claim, because the damages are the rest of a person’s life with one working eye.

Answer Capsule

Massachusetts patients who developed non-arteritic anterior ischemic optic neuropathy, NAION, while taking a GLP-1 drug can bring failure to warn, design defect and breach of warranty claims against the manufacturers. The claims are consolidated in MDL No. 3163 in the Eastern District of Pennsylvania before Judge Karen S. Marston, created by the JPML on December 15, 2025, and separate from the gastrointestinal GLP-1 litigation in MDL No. 3094 before the same judge. The JPML transfer order names Ozempic, Wegovy, Saxenda and Trulicity, so the litigation already covers liraglutide and dulaglutide, not only semaglutide. The core allegation is documentary: the European Medicines Agency concluded on June 6, 2025 that NAION is a very rare side effect of semaglutide, meaning up to 1 in 10,000, and required it on European product information, while the United States prescribing information reviewed for this page does not mention NAION anywhere in 34 pages. A Mass Eye and Ear study in JAMA Ophthalmology on July 3, 2024 reported hazard ratios of 4.28 in patients with type 2 diabetes and 7.64 in patients who were overweight or obese; the EMA’s population-level estimate is about a two-fold increase, or roughly one extra case per 10,000 person-years. Massachusetts claims run on the implied warranty of merchantability in M.G.L. c. 106 sec. 2-314, chapter 93A, and the three-year deadline in c. 260 sec. 2A subject to the discovery rule. Call Jim Glaser Law at (617) JIM-WINS; the first telephone consultation is offered without charge.

Every GLP-1 Drug, and Which Ones the Litigation Names

People remember the pen, not the molecule, and in this litigation the molecule is what matters. Here is the full family.

Brand name	Active ingredient	Maker	Approved for
Ozempic	Semaglutide (injection)	Novo Nordisk	Type 2 diabetes
Wegovy	Semaglutide (injection)	Novo Nordisk	Weight management
Rybelsus	Semaglutide (oral)	Novo Nordisk	Type 2 diabetes
Victoza	Liraglutide	Novo Nordisk	Type 2 diabetes
Saxenda	Liraglutide	Novo Nordisk	Weight management
Trulicity	Dulaglutide	Eli Lilly	Type 2 diabetes
Mounjaro	Tirzepatide	Eli Lilly	Type 2 diabetes
Zepbound	Tirzepatide	Eli Lilly	Weight management, sleep apnea
Byetta, Bydureon	Exenatide	AstraZeneca	Type 2 diabetes

The JPML transfer order creating the vision MDL names four of them specifically: Ozempic, Wegovy, Saxenda and Trulicity. That detail is worth more than it looks. Saxenda is liraglutide and Trulicity is dulaglutide, so the vision litigation already reaches beyond semaglutide even though the published science concentrates there. Several widely read summaries of this litigation list Mounjaro and Zepbound instead, which the transfer order does not name in that sentence.

If you took a compounded semaglutide from a medical spa, a telehealth service or an online seller rather than a branded pen, your situation is different again, because the defendant may be a compounding pharmacy rather than Novo Nordisk, and that changes the forum. It is still worth the call; it is just not the same case.

The Label Gap, Which Is the Whole Case in Two Documents

Failure to warn sounds like a legal abstraction. In this litigation it is two documents sitting next to each other.

Europe, June 6, 2025. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded its review and found that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people. It required the product information for Ozempic, Rybelsus and Wegovy to be updated to say so. It told patients who experience sudden vision loss or rapidly worsening eyesight to contact their doctor without delay, and directed that if NAION is confirmed, semaglutide should be stopped.

The United States. The Ozempic prescribing information reviewed for this page runs 34 pages. It carries a boxed warning about thyroid C-cell tumors. Its warnings and precautions section covers acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. Two of those, the severe gastrointestinal reactions and the aspiration warning, were added in January 2025, so the label does get updated when the agency decides a risk belongs on it.

The words NAION, ischemic optic neuropathy and optic neuropathy do not appear in that document at all. Diabetic retinopathy appears thirteen times; the eye stroke appears zero.

An American patient and an American prescriber reading the label they were given in 2025 or 2026 were not told about the injury European regulators had already named and required to be disclosed. That is the allegation, and unlike most allegations in pharmaceutical litigation, a juror can check it by reading two documents.

How Big Is the Risk, Honestly

Two credible sources give two different answers, and you deserve both rather than the larger one.

The study that started this came out of Boston. Researchers at Mass Eye and Ear led by Dr. Joseph Rizzo, director of the Neuro-Ophthalmology Service and a Harvard Medical School professor, published in JAMA Ophthalmology on July 3, 2024. The impetus was clinical rather than statistical: in one week in late summer 2023 the practice diagnosed three patients with NAION and all three were taking semaglutide. The published analysis covered a matched cohort of neuro-ophthalmic patients from that Boston practice and reported a hazard ratio of 4.28 in the type 2 diabetes cohort of 710 patients, and 7.64 in the overweight and obesity cohort of 979 patients. Over 36 months the cumulative incidence was 8.9 per cent against 1.8 per cent, and 6.7 per cent against 0.8 per cent.

The European Medicines Agency, reviewing large population studies rather than one referral practice, put the increase at roughly two-fold, corresponding to approximately one additional case of NAION per 10,000 person-years of treatment.

Both numbers can be right. A neuro-ophthalmology referral practice is where NAION patients end up, so the cases concentrate there in a way they do not in a general population database. The honest summary is that the association is real enough that European regulators acted on it, and that the size of the effect is genuinely contested. The researchers themselves said the study does not prove causation and that they do not know the mechanism.

That nuance is not a reason to skip the phone call. Causation in a pharmaceutical case is proved by experts on a full record, not by a reader weighing two percentages.

The Other GLP-1 Injuries, Because Vision Is Not the Only One

Brandon’s instruction for this page was to cover all of it, and the vision cases are the newest part of a larger picture.

Gastrointestinal injuries. This is the older and much larger litigation: MDL No. 3094, also before Judge Marston, covering gastroparesis or stomach paralysis, ileus, and intestinal obstruction. A 2023 study in JAMA by Sodhi and colleagues, using a database of roughly 16 million patients, compared GLP-1 users against people taking bupropion-naltrexone and reported adjusted hazard ratios of 9.09 for pancreatitis, 4.22 for bowel obstruction and 3.67 for gastroparesis. The confidence intervals on those figures are very wide, 1.25 to 66.00 on the pancreatitis estimate, so they establish a signal rather than a precise multiplier.

Injuries the American label already warns about. Acute pancreatitis. Acute gallbladder disease, including gallstones and cholecystitis. Acute kidney injury from the dehydration that severe vomiting causes. Diabetic retinopathy complications, which is a different eye problem from NAION and is already on the label. Hypoglycemia when combined with insulin or an insulin secretagogue.

Pulmonary aspiration under anesthesia. Added to the label in January 2025. These drugs slow stomach emptying, so a patient who fasted correctly before surgery can still have a full stomach, and can inhale the contents under sedation. Anyone scheduled for a procedure should tell the anesthesiologist they are on a GLP-1.

Thyroid C-cell tumors. The boxed warning, the most serious warning the FDA uses. In rodents semaglutide causes thyroid C-cell tumors; whether it does in humans is stated as unknown. The drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

If your injury is on this list rather than a vision one, the call is still worth making. It is simply a different docket.

Do You Have a Massachusetts Claim? A Short Checklist

1. The diagnosis. An eye doctor or neuro-ophthalmologist diagnosed NAION, ischemic optic neuropathy, or an eye stroke. A record that says only “vision loss” is a starting point, not a bar.
2. The exposure. You were taking a GLP-1 drug at the time, or had been recently. Pull the pharmacy printout; most pharmacies will print a full dispensing history on request and it takes ten minutes.
3. The sequence. The vision loss came after the drug started, not before.
4. The timing. The three-year clock in M.G.L. c. 260 sec. 2A has not run, measured under the discovery rule from when you knew or reasonably should have known a drug might be involved.
5. The gap. Nobody warned you. Given that the American label does not mention NAION, this is usually the easiest element in the case.

If four of those five are true, call. If you are unsure about any of them, that is what the free first consultation is for; sorting a maybe from a no is the work, and it is not work you should be doing alone.

What Massachusetts Law Adds That Other States Do Not

Two features of Massachusetts law matter to a claim like this.

The implied warranty of merchantability under M.G.L. c. 106 sec. 2-314 does the job here that strict product liability does in most states. A product that is not fit for its ordinary purpose breaches it, and a drug sold without a warning of a known serious risk can fail that test even though it works as intended for most people.

Chapter 93A is the one that changes the arithmetic. If a manufacturer’s conduct was an unfair or deceptive act in trade or commerce, and the violation was willful or knowing, c. 93A allows double or treble damages plus attorney fees. It requires a written demand letter served thirty days before suit. That is a Massachusetts-specific layer most of the country does not have, and in a case built on what a company knew and when, it is not decorative.

The three-year deadline in c. 260 sec. 2A runs under the discovery rule. A person who lost sight in 2022, was told it was one of those things, and first read about the GLP-1 connection this month has an argument that the clock started recently. It is an argument rather than a certainty, and it is exactly the kind of question a phone call resolves faster than a search engine.

Key Terms

• NAION. Non-arteritic anterior ischemic optic neuropathy: loss of blood flow to the optic nerve head, painless, usually one eye, generally permanent.
• Arteritic AION. The other form, driven by giant cell arteritis, which is ruled out during diagnosis and is a medical emergency treated with steroids.
• MDL. Multidistrict litigation: federal cases sharing common questions consolidated before one judge for pretrial work, then returned for trial. It is not a class action, and each claimant keeps their own case.
• Bellwether. An early representative trial used to show both sides how juries value the claims. None has happened in the GLP-1 vision litigation.
• Discovery rule. The Massachusetts principle that a limitations clock can start when a claimant knew or should have known their injury was caused by someone’s conduct.
• Chapter 93A demand letter. The written notice Massachusetts requires thirty days before filing a consumer-protection claim, and the document that opens the door to multiple damages.

Where the Litigation Stands Right Now

MDL No. 3163 began with 21 actions from three districts plus nine related tag-along cases, and has grown substantially since. Judge Marston is handling common pretrial work: what the manufacturers knew and when, general causation expert practice, and eventually the selection of bellwether trials.

No bellwether has been tried. No global settlement has been announced. Anyone quoting you a settlement figure for a GLP-1 eye case today is quoting a guess, and you should treat the confidence as a warning sign.

What that means practically is that this is an early-stage litigation rather than a closing window. It also means the evidentiary work, particularly pharmacy records and the eye records that establish the diagnosis, is worth doing now while it is easy to obtain.

Frequently Asked Questions

Q: Can I sue over vision loss from Ozempic in Massachusetts?

A: If you were diagnosed with NAION while taking Ozempic or another GLP-1 drug, you may be able to. The claims are consolidated in MDL No. 3163 in the Eastern District of Pennsylvania before Judge Karen S. Marston, created December 15, 2025, and Massachusetts residents are eligible to participate. Whether your specific facts support a claim depends on the diagnosis, the exposure dates and the limitations analysis. Call Jim Glaser Law at (617) JIM-WINS; the first telephone consultation is offered without charge.

Q: Which GLP-1 drugs are named in the vision loss lawsuits?

A: The JPML transfer order creating MDL 3163 names Ozempic, Wegovy, Saxenda and Trulicity, which means the litigation already covers semaglutide, liraglutide and dulaglutide. The broader GLP-1 family also includes Rybelsus and Victoza from Novo Nordisk, Mounjaro and Zepbound from Eli Lilly, and Byetta and Bydureon from AstraZeneca. If you lost vision on any GLP-1, the drug name and dates are the first things to establish, and the pharmacy record is more reliable than memory.

Q: Does the Ozempic label warn about blindness?

A: Not in the United States, based on the prescribing information reviewed for this page. That 34-page document warns about thyroid C-cell tumors in a boxed warning, and about pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity, gallbladder disease and pulmonary aspiration under anesthesia. It does not contain the word NAION or the phrase optic neuropathy. In Europe the position is different: the EMA required NAION to be added to the product information for Ozempic, Rybelsus and Wegovy on June 6, 2025.

Q: How much does a GLP-1 increase the risk of NAION?

A: The estimates differ and both are worth knowing. The Mass Eye and Ear study in JAMA Ophthalmology on July 3, 2024 reported hazard ratios of 4.28 in patients with type 2 diabetes and 7.64 in patients who were overweight or had obesity, drawn from one Boston neuro-ophthalmology practice. The European Medicines Agency, using large population studies, estimated roughly a two-fold increase, about one additional case per 10,000 person-years, and classified NAION as a very rare side effect. The researchers stated the study does not prove causation.

Q: How long do I have to file a Massachusetts GLP-1 claim?

A: Three years under M.G.L. c. 260 sec. 2A, with the discovery rule usually controlling when the three years began. Because most patients were never told a drug might be responsible for their vision loss, the argument is often that the clock started when the connection became knowable rather than on the date of the injury. That is fact-specific, so an older injury is worth a call rather than an assumption.

Q: What if my injury was stomach or bowel rather than vision?

A: Then your case belongs in the other litigation, MDL No. 3094, which covers gastroparesis, ileus and intestinal obstruction and sits before the same judge. The JPML deliberately kept the two separate when it created the vision MDL. The intake call sorts which docket fits before anything is filed, and the answer is usually obvious within a couple of minutes.

Q: I stopped taking the drug. Does that hurt my claim?

A: No. Stopping is what the European label now instructs when NAION is confirmed, and the claim is about the warning you were not given before the injury, not about what you did afterwards. If you stopped after losing vision in the first eye, note the date, because whether you were warned that the second eye could follow can matter.

Q: What does it cost to call?

A: Nothing. The first telephone consultation is offered without charge, and the line is answered 24 hours a day. If the firm accepts the matter, these cases are handled on contingency, meaning no attorney’s fee unless and until the matter resolves with a recovery to the client; case-related costs and expenses are addressed in the written fee agreement signed at intake.

Q: Is Jimmy Knows AI giving me legal advice?

A: No. This is general information about Massachusetts law and about a pending litigation, not legal advice, and reading it does not create an attorney-client relationship. Nothing here predicts an outcome in any case. Whether any of it applies to you depends on facts that are not in this article, including your diagnosis, your prescription history and your medical background. For advice about a specific situation, speak with a Massachusetts attorney.

Talking to a Lawyer

The hardest part of a case like this is that most people never connect the two events. Sight goes in one eye, a doctor explains it as an eye stroke, and the prescription in the medicine cabinet is never mentioned, because the American label never mentioned it either. People find out from a news story, sometimes years later.

If that describes you, or describes your mother or your husband, the call is short. What the firm needs is the drug name, the rough dates, and the name of the eye doctor who made the diagnosis. Everything else, the records, the pharmacy history, the analysis of whether the deadline has run, is work the firm does.

Jim Glaser Law can be reached at (617) JIM-WINS. The line is answered 24 hours a day. The first telephone consultation is offered without charge. Cases accepted on a contingency basis carry no attorney fee unless there is a recovery, and case-related costs and expenses are addressed in the written fee agreement signed at intake.

Related reading on this site: the Massachusetts GLP-1 vision loss practice page, Massachusetts weight loss drug claims for the stomach and bowel litigation, how long you have to file a Massachusetts injury claim, and what a 93A demand letter is.